Dark

Check out our API

MRTX
Mirati Therapeutics, Inc. Common Stock
stock NASDAQ

Inactive

Jan 22, 2024

58.70USD-0.170%(-0.10)20,994,430

Pre-market

0.00USD-100.000%(-58.80)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 21, 2022

12:14PM EST Mirati Therapeutics Posts 41% Objective Response Rate In Pretreated GI Cancer Patients Benzinga

10:02AM EST Mirati Presents Positive Data With Investigational Adagrasib In Patients With KRASG12C-Mutated Gastrointestinal Cancers RTTNews

10:02AM EST Mirati Therapeutics Highlights Presentation Of Data With Adagrasib In Patients With KRASG12C-Mutated Gastrointestinal Cancers Benzinga

10:02AM EST Mirati Therapeutics Presents Clinical Data With Investigational Adagrasib In Patients With KRASG12C-Mutated Gastrointestinal Cancers Benzinga

10:01AM EST Mirati Therapeutics Presents Positive Clinical Data with Investigational PR Newswire

Jan 4, 2022

04:30PM EST Mirati Therapeutics to Present at the J.P. Morgan 40th Annual Virtual PR Newswire

Dec 29, 2021

06:51PM EST Investigation Alert: Did You Lose Money on Your Stock? Johnson Fistel, LLP PR Newswire

Nov 23, 2021

04:33PM EST Mirati Therapeutics To Participate In Evercore ISI HealthCONx Conference Dec. 2 At 2:15 p.m. EST Benzinga

04:30PM EST Mirati Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx PR Newswire

Nov 22, 2021

07:50AM EST Mirati Therapeutics Inc. (MRTX) and Verastem Oncology (VSTM) have collaborated to evaluate the combination of Mirati's investigational KRASG12C inhibitor adagrasib with Verastem Oncology's investigational RAF/MEK inhibitor VS-6766 in KRASG12C-mutant non-small cell lung cancer (NSCLC), the companies said in a statement. RTTNews

07:41AM EST Mirati, Verastem Partner To Evaluate Adagrasib In Combination With VS-6766 In KRASG12C-Mutant Non-Small Cell Lung Cancer RTTNews

07:35AM EST Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer Benzinga

07:31AM EST Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in PR Newswire

07:30AM EST Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer Business Wire

Nov 19, 2021

11:57AM EST Expert Ratings For Mirati Therapeutics Benzinga

10:09AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 Benzinga

05:39AM EST BMO Capital Initiates Coverage On Mirati Therapeutics with Outperform Rating, Announces Price Target of $187 Benzinga

Nov 17, 2021

07:33AM EST Mirati Therapeutics Submits INDA To U.S. FDA Of MRTX1719 To Treat MTAP-Deleted Cancers RTTNews

07:32AM EST Mirati Therapeutics Announces Submission Of Investigational New Drug Application To US Food And Drug Administration Of MRTX1719 To Treat MTAP-Deleted Cancers Benzinga

07:31AM EST Application to U.S. Food and Drug Administration of MRTX1719 to Treat MTAP-Deleted Cancers PR Newswire

Nov 10, 2021

10:08PM EST Mirati Therapeutics Prices Underwritten Public Offering Of 3.45 Mln Shares At $145.00/shr RTTNews

09:12PM EST Mirati Therapeutics Announces Pricing of Public Offering of Common Stock PR Newswire

08:23AM EST The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance Benzinga

Nov 9, 2021

05:25PM EST Mirati Therapeutics Announces Proposed Public Offering Of $500M In Common Stock Benzinga

04:24PM EST Mirati Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire

11:42AM EST The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data Benzinga

11:07AM EST Mirati Therapeutics Q3 EPS $(1.55) Beats $(2.89) Estimate, Sales $71.79M Beat $10.62M Estimate Benzinga

09:03AM EST Mirati Therapeutics to Participate in the Stifel 2021 Virtual Healthcare PR Newswire

Nov 8, 2021

04:01PM EST Mirati Therapeutics Reports Third Quarter 2021 Financial Results and Recent PR Newswire

08:29AM EST The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Benzinga

05:06AM EST Earnings Scheduled For November 8, 2021 Benzinga

Nov 2, 2021

08:48AM EDT (MRTX) Alert: Did You Lose Money on Your Mirati Therapeutics Investment? PR Newswire

Nov 1, 2021

04:31PM EDT Mirati Therapeutics to Report Financial Results for Third Quarter 2021 and PR Newswire

03:23PM EDT Mid-Afternoon Market Update: loanDepot Surges After Q3 Results; Mirati Therapeutics Shares Slide Benzinga

12:14PM EDT Mid-Day Market Update: Dow Rises 50 Points; ANI Pharmaceuticals Shares Jump Benzinga

11:41AM EDT Mirati Therapeutics Reports COO, Chief Medical Officer Will Step Down Benzinga

07:47AM EDT Mirati Therapeutics Reports COO, Chief Medical Officer Well Step Down From Comapny Benzinga

Oct 7, 2021

04:31PM EDT Mirati Therapeutics Reports Collab With Sanofi For Phase 1/2 Study Evaulating Combo Of Adagrasib With SHP2 Inhibitor In KRAS G12C-Mutated Lung Cancer Benzinga

04:31PM EDT Combination of adagrasib with a SHP2 Inhibitor in KRAS G12C-mutated Lung Cancer PR Newswire

Oct 4, 2021

04:33PM EDT Mirati Therapeutics To Present New Research From Its Oncology Pipeline At AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Thursday, Oct. 7, 2021 Benzinga

04:33PM EDT Mirati Therapeutics To Present New Research From Oncology Pipeline At 2021 AACR-NCI-EORTC Virtual International Conference On Molecular Targets And Cancer Benzinga

04:31PM EDT Pipeline at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer PR Newswire

Sep 24, 2021

04:15PM EDT Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule PR Newswire

Sep 23, 2021

12:43PM EDT What 6 Analyst Ratings Have To Say About Mirati Therapeutics Benzinga

10:06AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021 Benzinga

04:58AM EDT Stifel Initiates Coverage On Mirati Therapeutics with Buy Rating, Announces Price Target of $202 Benzinga

Sep 21, 2021

01:51PM EDT Expert Ratings For Mirati Therapeutics Benzinga

08:10AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

07:50AM EDT Morgan Stanley Maintains Equal-Weight on Mirati Therapeutics, Raises Price Target to $173 Benzinga

07:15AM EDT Oppenheimer Maintains Perform on Mirati Therapeutics, Raises Price Target to $175 Benzinga

04:35AM EDT SVB Leerink Maintains Outperform on Mirati Therapeutics, Raises Price Target to $205 Benzinga

Sep 20, 2021

12:09PM EDT Why Mirati Therapeutics Stock Is Trading Higher Today Benzinga

08:38AM EDT Mirati Reports Positive Topline Data From Phase 2 Study RTTNews

08:25AM EDT Mirati Therapeutics Announces Long-term Survival Results From Exploratory Analysis Of Sitravatinib Plus Nivolumab RTTNews

08:21AM EDT Mirati Therapeutics To Present Long-Term Survival Results From Exploratory Analysis Of Sitravatinib Plus Nivolumab At ESMO 2021 Benzinga

08:20AM EDT Analysis of Sitravatinib plus Nivolumab in Patients with Non-squamous Non-Small Cell Lung Cancer Who are Resistant to Checkpoint Inhibitors PR Newswire

08:05AM EDT Mirati Therapeutics Appoints David Meek As CEO RTTNews

07:56AM EDT Mirati Therapeutics Appoints David Meek As Chief Executive Officer Benzinga

07:32AM EDT Mirati Therapeutics Announces Positive Topline Results From Phase 2 KRYSTAL-1 Study Evaluating Adagrasib RTTNews

07:31AM EDT Mirati Therapeutics Announces Phase 2 Topline Results For Investigational Adagrasib In Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer Benzinga

07:31AM EDT Investigational Adagrasib in Patients with KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer PR Newswire

Sep 19, 2021

09:55AM EDT Mirati Therapeutics Announced Clinical Data with Investigational Adagrasib Showed Adagrasib Alone and With Cetuximab Demonstrated Significant Clinical Activity and Broad Disease Control in Patients with KRAS G12C-Mutated Colorectal Cancer; Data to be Presented at ESMO Benzinga

09:47AM EDT Adagrasib as Monotherapy and in Combination with Cetuximab in Patients with KRAS G12C-Mutated Colorectal Cancer PR Newswire

09:46AM EDT The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions and Conference Presentations In The Spotlight Benzinga

Sep 15, 2021

04:24PM EDT Mirati Therapeutics To Host Virtual Investor Event Monday, Sept. 20, 2021 Benzinga

04:15PM EDT Mirati Therapeutics to Host Virtual Investor Event on Monday, September 20, 2021 PR Newswire

Aug 26, 2021

10:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2021 Benzinga

07:57AM EDT Morgan Stanley Initiates Coverage On Mirati Therapeutics with Equal-Weight Rating, Announces Price Target of $160 Benzinga

Aug 25, 2021

04:31PM EDT Mirati Therapeutics Clinical Research at ESMO Congress 2021 to Highlight Progress with Investigational Adagrasib and Sitravatinib in Patients with Lung and Colorectal Cancers Benzinga

04:30PM EDT Progress with Investigational Adagrasib and Sitravatinib in Patients with Lung and Colorectal Cancers PR Newswire

Aug 9, 2021

06:12AM EDT HC Wainwright & Co. Maintains Buy on Mirati Therapeutics, Lowers Price Target to $247 Benzinga

Aug 5, 2021

06:07PM EDT Mirati Therapeutics Q2 EPS $(3.23) Down From $(1.89) YoY Benzinga

04:15PM EDT Mirati Therapeutics Reports Second Quarter 2021 Financial Results and Recent PR Newswire

Jul 23, 2021

09:26AM EDT Mirati Therapeutics Posts Study Titled 'Phase 1/1B Study in Patients With Cancer KRYSTAL 14' To ClinicalTrials.Gov; Study Is Recruiting Benzinga

Jul 2, 2021

04:04PM EDT Mirati Therapeutics S-3 Shows Registration For $500M Mixed Securities Shelf Offering Benzinga

Jun 25, 2021

09:27AM EDT Mirati's KRAS Inhibitor Receives FDA Breakthrough Tag For Lung Cancer Harboring KRAS Mutation Benzinga

07:32AM EDT The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs Benzinga

06:04AM EDT A Peek Into The Markets: US Stock Futures Up Following Thursday's Rally; Nike Posts Upbeat Results Benzinga

Jun 24, 2021

05:30PM EDT Shares of Mirati Therapeutics, Inc. (MRTX) gained nearly 5% in extended trading session on Thursday after the clinical-stage oncology company announced that the U.S. FDA has granted breakthrough therapy designation to adagrasib for treatment of patients with advanced non-small cell lung cancer harboring the KRAS G12C mutation. RTTNews

04:44PM EDT Mirati Therapetuics Reports Its Adagrasib Received Breakthrough Therapy Designation From FDA For Patients With Advanced Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation Benzinga

04:43PM EDT U.S. Food and Drug Administration for Patients with Advanced Non-Small Cell Lung Cancer Harboring the KRAS G12C Mutation PR Newswire

Jun 4, 2021

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 4, 2021 Benzinga

08:11AM EDT Citigroup Upgrades Mirati Therapeutics to Buy Benzinga

Jun 2, 2021

04:15PM EDT Mirati Therapeutics to Take Part in the 42nd Annual Goldman Sachs Global PR Newswire

Jun 1, 2021

08:58AM EDT Mirati Therapeutics Inc. (MRTX) and Zai Lab Limited (ZLAB) said that they have reached a collaboration and license agreement for adagrasib, a small-molecule KRASG12C inhibitor, in Greater China. RTTNews

07:47AM EDT Mirati Therapeutics, Zai Lab Enter Collaboration To Develop Adagrasib In Greater China RTTNews

07:32AM EDT Mirati Therapeutics And Zai Lab Enter Into Collaboration To Develop And Commercialize Adagrasib In Greater China; Mirati To Receive $65M Upfront Payment And Up To $273M In Potential Milestones Benzinga

07:32AM EDT Mirati Therapeutics And Zai Lab Collaborate To Develop Adagrasib In Greater China RTTNews

07:31AM EDT Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and PR Newswire

07:30AM EDT Mirati Therapeutics and Zai Lab Enter Into a Collaboration GlobeNewswire Inc

May 26, 2021

07:33AM EDT The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing Benzinga

May 25, 2021

04:13PM EDT QIAGEN Reports Partnership With Mirati Therapeutics To Develop KRASG12C Companion Diagnostic For Non-Small Cell Lung Cancer Benzinga

May 17, 2021

10:10AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 17, 2021 Benzinga

08:11AM EDT 10 Biggest Price Target Changes For Monday Benzinga

06:57AM EDT Oppenheimer Downgrades Mirati Therapeutics to Perform, Lowers Price Target to $160 Benzinga

May 10, 2021

10:16AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2021 Benzinga

08:43AM EDT 10 Biggest Price Target Changes For Monday Benzinga

06:58AM EDT Jefferies Upgrades Mirati Therapeutics to Buy, Lowers Price Target to $196 Benzinga

06:13AM EDT HC Wainwright & Co. Maintains Buy on Mirati Therapeutics, Lowers Price Target to $251 Benzinga

May 6, 2021

05:37PM EDT Mirati Therapeutics Q1 EPS $(2.67) Down From $(2.02) YoY Benzinga

04:16PM EDT Mirati Therapeutics Reports First Quarter 2021 Financial Results and Recent PR Newswire

Apr 10, 2021

02:35PM EDT Inhibition that Selectively Targets the PRMT5/MTA Complex in MTAP-Deleted Cancer Models PR Newswire

09:19AM EDT The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight Benzinga

Mar 31, 2021

07:34AM EDT Mirati Therapeutics Names Shalini Sharp New Independent Director RTTNews

07:31AM EDT Mirati Therapeutics Board Elects Shalini Sharp as New Independent Director PR Newswire

Mar 10, 2021

04:41PM EST Mirati Therapeutics Says To present Late-Breaking Data At American Association For Cancer Research 2021; Co Says Data 'Advance The Understanding Of Synthetic Lethal PRMT5 Inhibitors In MTAP-Deleted Cancers' Benzinga

04:40PM EST Understanding of Synthetic Lethal PRMT5 Inhibitors in MTAP-Deleted Cancers at AACR 2021 PR Newswire

Mar 1, 2021

11:52AM EST Oppenheimer Maintains Outperform on Mirati Therapeutics, Lowers Price Target to $255 Benzinga

06:53AM EST HC Wainwright & Co. Maintains Buy on Mirati Therapeutics, Lowers Price Target to $255 Benzinga

Feb 25, 2021

05:31PM EST Mirati Therapeutics Q4 EPS $(2.08) Down From $(1.83) YoY, Sales $1.71M Up From $526.00K YoY Benzinga

04:25PM EST Mirati Therapeutics Reports Fourth Quarter And Full-Year 2020 Financial Results PR Newswire

Feb 18, 2021

04:15PM EST Mirati Therapeutics To Present At Upcoming Healthcare Conferences PR Newswire

Feb 10, 2021

07:28AM EST MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors Benzinga

07:01AM EST MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And PR Newswire

Feb 4, 2021

04:31PM EST Mirati Therapeutics To Present At Guggenheim Healthcare Talks 2021 Oncology Days PR Newswire

Jan 15, 2021

12:27PM EST HC Wainwright & Co. Maintains Buy on Mirati Therapeutics, Lowers Price Target to $257 Benzinga

Jan 11, 2021

08:20AM EST Resolution Bioscience Announces Companion Diagnostic Collaboration With Mirati Therapeutics Benzinga

Jan 4, 2021

05:20PM EST Mirati Therapeutics To Present At The 39th Annual J.P. Morgan Healthcare PR Newswire

Dec 16, 2020

09:11AM EST Credit Suisse Maintains Outperform on Mirati Therapeutics, Raises Price Target to $285 Benzinga

Dec 15, 2020

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

Dec 11, 2020

08:11AM EST The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street Benzinga

Dec 8, 2020

09:36AM EST Benzinga's Top Upgrades, Downgrades For December 8, 2020 Benzinga

07:24AM EST JMP Securities Initiates Coverage On Mirati Therapeutics with Market Perform Rating Benzinga

Dec 2, 2020

07:35AM EST The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod Benzinga

Nov 23, 2020

04:30PM EST Mirati Therapeutics To Participate In The 2020 Evercore ISI HealthCONx PR Newswire

Nov 17, 2020

08:42AM EST B of A Securities Downgrades Mirati Therapeutics to Underperform, Announces $196 Price Target Benzinga

Nov 9, 2020

06:08AM EST HC Wainwright & Co. Maintains Buy on Mirati Therapeutics, Raises Price Target to $265 Benzinga

Nov 5, 2020

04:31PM EST Mirati Therapeutics To Participate In The 29th Annual Credit Suisse Virtual PR Newswire

09:48AM EST Piper Sandler Maintains Overweight on Mirati Therapeutics, Raises Price Target to $260 Benzinga

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

Nov 4, 2020

04:51PM EST Mirati Therapeutics Q3 EPS $(1.96) Down From $(1.38) YoY, Sales $11.42M Up From $988.00K YoY Benzinga

04:16PM EST Mirati Therapeutics Reports Third Quarter 2020 Financial Results And Recent PR Newswire

Nov 2, 2020

08:32AM EST 10 Biggest Price Target Changes For Monday Benzinga

07:59AM EST H.C. Wainwright Maintains Buy on Mirati Therapeutics, Lowers Price Target to $233 Benzinga

Oct 30, 2020

05:10PM EDT Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And PR Newswire

08:09AM EDT The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts Benzinga

Oct 28, 2020

05:46AM EDT Mirati Therapeutics Priced 4.3M Share Public Offering Of Common Stock @$202/Share Benzinga

Oct 27, 2020

09:06PM EDT Mirati Therapeutics Prices Underwritten Public Offering Of 4.34 Mln Shares At $202.00/shr RTTNews

08:05PM EDT Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock PR Newswire

08:25AM EDT The Daily Biotech Pulse: Catabasis Halts Duchenne Muscular Dystrophy Study, Lilly's COVID-19 Trial Disappointment, Merck, Pfizer Earnings Benzinga

08:21AM EDT Credit Suisse Maintains Outperform on Mirati Therapeutics, Raises Price Target to $225 Benzinga

Oct 26, 2020

04:48PM EDT Mirati Therapeutics Reports $700M Common Stock Offering Benzinga

04:47PM EDT Mirati Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire

11:35AM EDT Why Mirati's Stock Is Trading Higher Today Benzinga

09:57AM EDT Mirati Therapeutics, Inc. (MRTX) shares are rising on Monday morning trade as the clinical-stage oncology company presented deep and durable anti-tumor activity for Adagrasib in non-small cell lung cancer, colorectal cancer, and other solid tumors. RTTNews

08:14AM EDT 10 Biggest Price Target Changes For Monday Benzinga

08:01AM EDT Piper Sandler Maintains Overweight on Mirati Therapeutics, Raises Price Target to $210 Benzinga

07:18AM EDT SVB Leerink Maintains Outperform on Mirati Therapeutics, Raises Price Target to $195 Benzinga

06:53AM EDT HC Wainwright & Co. Maintains Buy on Mirati Therapeutics, Raises Price Target to $238 Benzinga

Oct 25, 2020

02:32PM EDT Barron's Picks And Pans: Coca-Cola, Sprouts Farmers Market, Mirati Therapeutics And More Benzinga

10:56AM EDT Mirati Therapeutics Reports Investigational Adagrasib (MRTX849) Preliminary Data Demonstrating Tolerability and Durable Anti-Tumor Activity With 45% Confirmed ORR and 96% DCR across Phase 1/1b and Phase 2 Monotherapy Cohorts in Patients with Advanced NSCLC Benzinga

10:45AM EDT Data Demonstrating Tolerability and Durable Anti-Tumor Activity as well as Initial MRTX1133 Preclinical Data PR Newswire

09:21AM EDT Barron's Picks And Pans: Coca-Cola, Sprouts Farmers Market, Mirati Therapeutics And More Benzinga

Oct 21, 2020

08:36AM EDT 10 Biggest Price Target Changes For Wednesday Benzinga

07:26AM EDT BMO Capital Maintains Market Perform on Mirati Therapeutics, Raises Price Target to $176 Benzinga

Oct 16, 2020

11:14AM EDT Mirati Therapeutics Option Alert: Nov 20 $230 Calls Sweep (16) above Ask!: 45 @ $12.487 vs 154 OI; Earnings 11/2 After Close [est] Ref=$195.215 Benzinga

08:16AM EDT 10 Biggest Price Target Changes For Friday Benzinga

06:59AM EDT HC Wainwright & Co. Maintains Buy on Mirati Therapeutics, Raises Price Target to $222 Benzinga

Oct 15, 2020

04:30PM EDT International Virtual Conference On Molecular Targets And Therapeutics (ENA) PR Newswire

Oct 8, 2020

08:44AM EDT 10 Biggest Price Target Changes For Thursday Benzinga

07:56AM EDT Credit Suisse Reiterates Outperform on Mirati Therapeutics, Raises Price Target to $190 Benzinga

Sep 28, 2020

11:37AM EDT B of A Securities Initiates Coverage On Mirati Therapeutics with Neutral Rating, Announces Price Target of $172 Benzinga

Sep 21, 2020

09:40AM EDT Piper Sandler Maintains Overweight on Mirati Therapeutics, Raises Price Target to $170 Benzinga

09:13AM EDT Oppenheimer Maintains Outperform on Mirati Therapeutics, Raises Price Target to $190 Benzinga

Sep 18, 2020

09:31AM EDT Benzinga's Top Upgrades, Downgrades For September 18, 2020 Benzinga

08:17AM EDT Citigroup Downgrades Mirati Therapeutics to Neutral, Raises Price Target to $183 Benzinga

08:07AM EDT Mirati Therapeutics Presents Phase 2 Data On Sitravatinib RTTNews

08:02AM EDT Mirati Announces Updated Clinical Results From Phase 2 Study Evaluating Sitravatinib In Combination With Nivolumab RTTNews

08:01AM EDT Mirati Therapeutics Highlights Presentation Of Phase 2 Data On Sitravatinib In Combo With Nivolumab In Urothelial Cancer At European Society For Medical Oncology Sept. 19-21 Benzinga

08:01AM EDT Mirati Therapeutics Presents Phase 2 Data On Sitravatinib In Combination With PR Newswire

Sep 17, 2020

10:34AM EDT HC Wainwright & Co. Maintains Buy on Mirati Therapeutics, Raises Price Target to $185 Benzinga

08:06AM EDT Boehringer Ingelheim And Mirati Therapeutics Announce Clinical Collaboration To Study BI 1701963, A SOS1::pan-KRAS Inhibitor In Combination With MRTX849, A KRAS G12C Selective Inhibitor Benzinga

08:02AM EDT Study BI 1701963, A SOS1::pan-KRAS Inhibitor In Combination With MRTX849, A KRAS G12C Selective Inhibitor PR Newswire

Sep 3, 2020

04:31PM EDT Mirati Therapeutics To Participate In Citi's 15th Annual Biopharma Virtual PR Newswire

Aug 14, 2020

08:26AM EDT The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal Benzinga

Aug 13, 2020

08:40AM EDT Strata Oncology Announces Partnership To Broaden Enrollment In Mirati' Trial Of MRTX849 RTTNews

08:06AM EDT Strata Oncology Announces Partnership To Broaden Enrollment In Mirati Therapeutics' Clinical Trial Of MRTX849, A Novel KRAS G12C Selective Inhibitor Benzinga

08:03AM EDT Therapeutics' Clinical Trial of MRTX849, a Novel KRAS G12C Selective Inhibitor PR Newswire

Aug 7, 2020

10:24AM EDT Credit Suisse Maintains Outperform on Mirati Therapeutics, Raises Price Target to $140 Benzinga

Aug 6, 2020

05:33PM EDT Mirati Therapeutics Q2 EPS $(1.89) Down From $(1.26) YoY Benzinga

04:16PM EDT Mirati Therapeutics Reports Second Quarter 2020 Financial Results And Recent PR Newswire

Jul 29, 2020

10:01AM EDT Credit Suisse Maintains Outperform on Mirati Therapeutics, Raises Price Target to $135 Benzinga

Share